Breast Cancer – EA1131 – Triple Negative

Sponsor: Easton Cooperative Group (ECOG)

Study:  EA1131

Phase III

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Eligibility Criteria for Screening and Molecular Profiling (Step 0)

  • Age ≥ 18 years
  • Confirmed triple negative invasive breast cancer ER-, PR- HER2- (stage II or III)
  • Completed definitive surgery of primary tumor with residual invasive cancer at time of surgery
  • Radiotherapy may be given before or after protocol treatment
  • Must have completed neoadjuvant taxane ± anthracycline–based chemotherapy

Exclusion Criteria:

  • Cannot have received cisplatin, carboplatin, or capecitabine in the  neoadjuvant setting

To learn more about available clinical research trials contact:

Deborah Brunetti, RN, CRC
Hunterdon Regional Cancer Center – Research Department
2100 Wescott Drive
Flemington, NJ 08822
908-237-2330 option #3